Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
09 2020
Historique:
received: 06 09 2019
accepted: 13 05 2020
pubmed: 1 7 2020
medline: 5 11 2020
entrez: 1 7 2020
Statut: ppublish

Résumé

A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail global control efforts. Although the mechanisms remain poorly clarified, drug-resistant strains are widely believed to be less infectious than drug-susceptible strains. Consequently, we hypothesized that lower proportions of patients with drug-resistant TB would have culturable Mycobacterium tuberculosis from respirable, cough-generated aerosols compared to patients with drug-susceptible TB, and that multiple factors, including mycobacterial genomic variation, would predict culturable cough aerosol production. We enumerated the colony forming units in aerosols (≤10 µm) from 452 patients with TB (227 with drug resistance), compared clinical characteristics, and performed mycobacterial whole-genome sequencing, dormancy phenotyping and drug-susceptibility analyses on M. tuberculosis from sputum. After considering treatment duration, we found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive. Surprisingly, neither mycobacterial genomic variants, lineage, nor dormancy status predicted cough aerosol culture positivity. However, mycobacterial sputum bacillary load and clinical characteristics, including a lower symptom score and stronger cough, were strongly predictive, thereby supporting targeted transmission-limiting interventions. Effective treatment largely abrogated cough aerosol culture positivity; however, this was not always rapid. These data question current paradigms, inform public health strategies and suggest the need to redirect TB transmission-associated research efforts toward host-pathogen interactions.

Identifiants

pubmed: 32601338
doi: 10.1038/s41591-020-0940-2
pii: 10.1038/s41591-020-0940-2
pmc: PMC8353872
mid: NIHMS1726937
doi:

Substances chimiques

Aerosols 0
Antitubercular Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1435-1443

Subventions

Organisme : Wellcome Trust
ID : 099854/Z/12/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI104817
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : MR/S027777/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S03563X/1
Pays : United Kingdom

Références

Sci Rep. 2018 Mar 29;8(1):5382
pubmed: 29599463
Bull Int Union Tuberc. 1975;50(1):107-21
pubmed: 1218286
Mol Microbiol. 2014 Mar;91(6):1106-19
pubmed: 24417450
PLoS Pathog. 2006 Jun;2(6):e61
pubmed: 16789833
Lancet Respir Med. 2017 Apr;5(4):269-281
pubmed: 28109869
Clin Infect Dis. 2008 Nov 1;47(9):1135-42
pubmed: 18823268
Infect Genet Evol. 2012 Jun;12(4):755-66
pubmed: 22365971
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1208-1219
pubmed: 29877726
Lancet Respir Med. 2017 Mar 15;:
pubmed: 28344011
Int J Tuberc Lung Dis. 2014 Sep;18(9):1019-25
pubmed: 25189547
Lancet Infect Dis. 2013 Feb;13(2):137-46
pubmed: 23158499
Int J Tuberc Lung Dis. 2016 Mar;20(3):329-34
pubmed: 27046713
Antimicrob Agents Chemother. 2014;58(1):11-8
pubmed: 24100497
J Clin Microbiol. 2015 Nov;53(11):3633-5
pubmed: 26292310
Microbiology (Reading). 2002 Oct;148(Pt 10):2951-8
pubmed: 12368428
Clin Infect Dis. 2015 Jul 1;61(1):1-8
pubmed: 25778753
Clin Infect Dis. 2007 May 15;44(10):1349-57
pubmed: 17443474
Lancet Infect Dis. 2017 Apr;17(4):441-450
pubmed: 28063795
Nat Genet. 2011 Dec 18;44(1):106-10
pubmed: 22179134
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Am J Respir Crit Care Med. 2013 May 1;187(9):1007-15
pubmed: 23306539
Bioinformatics. 2012 Nov 15;28(22):2991-3
pubmed: 23014632
PLoS One. 2013;8(3):e59414
pubmed: 23527189
BMC Infect Dis. 2019 Mar 12;19(1):244
pubmed: 30866840
Nat Genet. 2014 Mar;46(3):279-86
pubmed: 24464101
Epidemiology. 2013 May;24(3):395-400
pubmed: 23446314
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Lancet. 2014 Apr 5;383(9924):1230-9
pubmed: 24439237
Am J Respir Crit Care Med. 2004 Mar 1;169(5):604-9
pubmed: 14656754
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):338-42
pubmed: 8990210
Scand J Infect Dis. 2008;40(2):111-20
pubmed: 17852907
Tubercle. 1976 Dec;57(4):275-99
pubmed: 827837
Lancet Infect Dis. 2015 Oct;15(10):1193-1202
pubmed: 26116186
Int J Infect Dis. 2019 Feb;79:65-71
pubmed: 30395979
Drugs. 2014 Jul;74(10):1063-72
pubmed: 24962424
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1532-1540
pubmed: 27387272
Am J Respir Crit Care Med. 2012 Sep 1;186(5):450-7
pubmed: 22798319
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
Am Rev Respir Dis. 1962 Apr;85:511-25
pubmed: 14492300
Tuberculosis (Edinb). 2011 Jul;91(4):329-38
pubmed: 21478054
J Clin Microbiol. 2006 Jan;44(1):254-6
pubmed: 16390984
Eur Respir J. 2017 Oct 26;50(4):
pubmed: 29074544
Antimicrob Agents Chemother. 2013 Feb;57(2):827-32
pubmed: 23208709
Nat Genet. 2013 Oct;45(10):1183-9
pubmed: 23995135
Am Rev Respir Dis. 1960 Sep;82:358-69
pubmed: 13835667
Clin Infect Dis. 2010 Aug 15;51(4):371-8
pubmed: 20624064
Infect Immun. 2006 Jul;74(7):3790-803
pubmed: 16790751
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Int J Tuberc Lung Dis. 2010 Jan;14(1):119-21
pubmed: 20003705
Genome Med. 2015 May 27;7(1):51
pubmed: 26019726
Clin Infect Dis. 2016 Jul 1;63(1):10-20
pubmed: 27025837

Auteurs

Grant Theron (G)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Jason Limberis (J)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

Rouxjeane Venter (R)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Liezel Smith (L)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.
DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Elize Pietersen (E)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

Aliasgar Esmail (A)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

Greg Calligaro (G)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

Julian Te Riele (J)

Brooklyn Chest Hospital, Cape Town, South Africa.

Marianna de Kock (M)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Paul van Helden (P)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Tawanda Gumbo (T)

Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center, Dallas, TX, USA.

Taane G Clark (TG)

Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Faculty of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine, London, UK.

Kevin Fennelly (K)

Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Robin Warren (R)

DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Keertan Dheda (K)

Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa. keertan.dheda@uct.ac.za.
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK. keertan.dheda@uct.ac.za.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH